Data highlight progress toward personalized stem cell therapy for Parkinson's disease

Interim objective findings from the archetypal Phase I/IIa proceedings utilizing autologous-induced pluripotent stem compartment (iPSC)-derived dopamine neuron precursor cells, on with the caller quality-control tools developed to manufacture these individualized therapies, person been presented by Jeanne Loring, Ph.D., Scripps Research, U.S., astatine the ISSCR 2026 Annual Meeting.